Inhibition of all-TRANS-retinoic acid metabolism by R116010 induces antitumour activity
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
All-trans-retinoic acid is a potent inhibitor of cell proliferation and inducer of differentiation. However, the clinical use of all-trans-retinoic acid in the treatment of cancer is significantly hampered by its toxicity and the prompt emergence of resistance, believed to be caused by increased all-trans-retinoic acid metabolism. Inhibitors of all-trans-retinoic acid metabolism may therefore prove valuable in the treatment of cancer. In this study, we characterize R116010 as a new anticancer drug that is a potent inhibitor of all-trans-retinoic acid metabolism. In vitro, R116010 potently inhibits all-trans-retinoic acid metabolism in intact T47D cells with an IC(50)-value of 8.7 nM. In addition, R116010 is a selective inhibitor as indicated by its inhibition profile for several other cytochrome P450-mediated reactions. In T47D cell proliferation assays, R116010 by itself has no effect on cell proliferation. However, in combination with all-trans-retinoic acid, R116010 enhances the all-trans-retinoic acid-mediated antiproliferative activity in a concentration-dependent manner. In vivo, the growth of murine oestrogen-independent TA3-Ha mammary tumours is significantly inhibited by R116010 at doses as low as 0.16 mg kg(-1). In conclusion, R116010 is a highly potent and selective inhibitor of all-trans-retinoic acid metabolism, which is able to enhance the biological activity of all-trans-retinoic acid, thereby exhibiting antitumour activity. R116010 represents a novel and promising anticancer drug with an unique mechanism of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Muindi, J., Frankel, Sr., Miller, W. J., Jakubowski, A., Scheinberg, D., Young, C., Dmitrovsky, E., & Warrell, R. J. (1992) · Blood · doi:10.1182/blood.v79.2.299.299 · Cited by 314
Cited by
Imidazoles as potential anticancer agents
Ali, I., Lone, M. N., & Aboul-Enein, H. Y. (2017) · Med. Chem. Commun. · doi:10.1039/c7md00067g · Cited by 409
Retinoids in cancer therapy and chemoprevention: Promise meets resistance
Freemantle, S. J., Spinella, M. J., & Dmitrovsky, E. (2003) · Oncogene · doi:10.1038/sj.onc.1206936 · Cited by 312
Cytochrome P450s in the Regulation of Cellular Retinoic Acid Metabolism
Catharine Ross, A., & Zolfaghari, R. (2011) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-072610-145127 · Cited by 296
Ross, A. C. (2003) · The Journal of Nutrition · doi:10.1093/jn/133.1.291s · Cited by 161
Metadata
- Authors
- Van heusden, J., Van Ginckel, R., Bruwiere, H., Moelans, P., Janssen, B., Floren, W., van der Leede, B. J., van Dun, J., Sanz, G., Venet, M., Dillen, L., Van Hove, C., Willemsens, G., Janicot, M., & Wouters, W.
- Venue
- British Journal of Cancer
- Published
- 2002-02
- Volume
- 86
- Issue
- 4
- Pages
- 605-611
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2017038168
- Cited by
- 86
- References
- 1
- FWCI
- 1.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of all-TRANS-retinoic acid metabolism by R116010 induces antitumour activity. https://app.cochat.ai/papers/10.1038/sj.bjc.6600056
- The paper
- Van heusden, J., Van Ginckel, R., Bruwiere, H., Moelans, P., Janssen, B., Floren, W., van der Leede, B. J., van Dun, J., Sanz, G., Venet, M., Dillen, L., Van Hove, C., Willemsens, G., Janicot, M., & Wouters, W. (2002). Inhibition of all-TRANS-retinoic acid metabolism by R116010 induces antitumour activity. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6600056
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.